Two tools, one goal: give clinicians enough certainty in the room to clear benign spots, and keep watching afterward, so patients face fewer unnecessary biopsies.
A patient spots a new or changing mark and books in with their GP or nurse.
The point-of-care scanner the clinician uses, in the room.
The companion app patients use to capture at home.
94% diagnostic accuracy in a pilot study at the Skin Health Institute, with four medical clinicians and thirty patients endorsing the tool for its clinical value and ease of use.
Equally accurate across skin tones, by design.
A multi-center trial with MoleMap Australia is testing DeepDerm across real-world clinics, working toward regulatory approval from the TGA.
DeepDerm's technology has not received regulatory clearance and is not available for sale.
Whether you are a clinician, a research partner, or a health system exploring AI-augmented care, we would like to hear from you.
